Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSD-001 SAD Study in Healthy Participants
NCT06702332Phase 1Completed
- Sponsor
- Mindstate Design Labs
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Mental health disorders comparing Active Treatment: MSD-001 with Placebo Comparator (2 arms). Primary endpoint: Safety and Tolerability of MSD-001 up to 30 days. Started Nov 2024; status: completed.
02
Drugs
MSD-001
03
Conditions
Mental health disorders
Beyond the preview
Go deeper on NCT06702332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06702332.